Liu Jung-sen notes that such an approach aims at preventing metastasis, but controversy remains due to the high cost of chemotherapy, the suffering it causes patients, and lack of evidence of its relative effectiveness. While chemotherapy is not generally favored in Taiwan, and Japanese research shows little difference in five-year survival rates, it does show higher ten-year survival rates for those undergoing chemotherapy.
劉榮森指出，開刀之後繼續做化療的目的在杜絕移轉，但由於化療花費甚鉅，病人覺得痛苦難挨，又沒有證據顯示效果較佳，因而爭議較大，一般傾向於不做，但根據日本的研究，儘管五年存活率看不出差距，但比較十年後，曾做過化療的患者的確存活率較高。